Details of the Drug Reposition

General Information of This Drug (ID: DMDQOWT)

Drug Name
MOR-208   DMDQOWT
Synonyms XmAb CD19; XENP-5574; XENP-5603; XmAb-5574; Anti-CD19 humanized mAb (cancer/autoimmune disease), Xencor; Anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 2/3 [1]
------------------------------------------------------------------------------------
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 2 [1]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 2 [2]
Autoimmune diabetes DISW6UF1 5A10 Phase 2 [3]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01685008) Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin Lymphoma (NHL). U.S. National Institutes of Health.